Merck & Co. stock pre-market at EUR 128.39: plus 0.00 percent
Published on 10/01/2026 at 08:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. stock was at EUR 128.39 in pre-market trading at 8:17 a.m. CEST on October 1, 2026, unchanged at plus 0.00 percent versus the prior close of EUR 128.39 at Lang & Schwarz on September 30, 2026.
Pre-market price
The Lang & Schwarz bid was EUR 128.10 and the ask was EUR 128.68. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Merck & Co. stock.
Remigromig reaches trial endpoint
In a September 24, 2026 release, Merck & Co. said its investigational remigromig met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema. Both the 0.5-milligram and 0.8-milligram doses demonstrated non-inferiority to 0.5-milligram ranibizumab for mean change from baseline in best-corrected visual acuity at week 52.
Merck said both doses were generally well tolerated, while higher rates of proliferative diabetic retinopathy, vitreous hemorrhage and treatment discontinuations due to adverse events were observed in the remigromig groups compared with ranibizumab. The company said further analyses are underway. The one-year results are scheduled for presentation at the American Academy of Ophthalmology annual meeting on October 10, 2026.
